First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

2025-523101-15-00 Protocol GCT3018-01 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 16 Feb 2026 · Status Ongoing, recruiting · 2 EU/EEA countries · 6 sites · Protocol GCT3018-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 40
Countries 2
Sites 6

Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Key facts

Sponsor
Genmab A/S
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
16 Feb 2026 → ongoing
Decision date (initial)
2026-01-16
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

VersionLevelCodeTermSystem organ class
26.0 PT 10088023 Myelodysplastic syndrome with excess blasts 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Genmab A/S

Sponsor organisation
Genmab A/S
Address
Carl Jacobsens Vej 30
City
Valby
Postcode
2500
Country
Denmark

Scientific contact point

Organisation
Genmab A/S
Contact name
Clinical Trial Information

Public contact point

Organisation
Genmab A/S
Contact name
Clinical Trial Information

Locations

2 EU/EEA countries · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Denmark Ongoing, recruiting 16 2
Spain Ongoing, recruiting 24 4
Rest of world 0

Investigational sites

Denmark

2 sites · Ongoing, recruiting
Region Midtjylland
Department of Hematology, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N
Rigshospitalet
Department of Haemotology, Blegdamsvej 9, 2100, Copenhagen Oe

Spain

4 sites · Ongoing, recruiting
Hospital Universitari Vall D Hebron
Haematology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Y Politecnico La Fe
Haematology, Avenida Fernando Abril Martorell 106, 46026, Valencia
Hospital Universitario 12 De Octubre
Haematology, Avenida De Cordoba Sn, 28041, Madrid
Hospital Clinic De Barcelona
Haematology, Calle Villarroel 170, 08036, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Denmark 2026-02-16 2026-02-16
Spain 2026-05-07 2026-05-07

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-11-12 Denmark Acceptable
2026-01-09
2026-01-16
2 SUBSEQUENT ADDITION OF MSC APP-2 2026-02-03 Acceptable
2026-01-09
2026-03-11